Derazantinib

Drug Overview

Derazantinib is an advanced oral medication used in precision oncology. It is a highly specialized “targeted therapy” designed to interfere with specific proteins that allow cancer cells to grow and spread. Unlike traditional chemotherapy, which affects all fast-growing cells in the body, derazantinib is engineered to be a “smart drug” that focuses on tumors with specific genetic changes.

Here are the key details about this medication:

• Generic Name: Derazantinib (formerly known as ARQ 087).
• US Brand Names: None at this time. It is currently an investigational drug.
• Drug Class: Kinase Inhibitor / FGFR (Fibroblast Growth Factor Receptor) Inhibitor.
• Route of Administration: Oral (taken by mouth as a tablet).
• FDA Approval Status: Investigational. It has received “Orphan Drug” designation for certain bile duct cancers but is still being evaluated in clinical trials for full public approval.

What Is It and How Does It Work? (Mechanism of Action)

To understand how derazantinib works, it helps to imagine the cancer cell as a machine that is stuck in the “ON” position. For certain cancers, this happens because of a mistake in a protein called the Fibroblast Growth Factor Receptor (FGFR).

The FGFR Pathway

In healthy cells, the FGFR protein acts like an antenna on the cell surface. It waits for a signal to tell the cell to grow or repair itself. In some cancers, the genes that make this “antenna” get fused or mutated. This causes the antenna to send a constant, nonstop signal to the cell to divide and form a tumor.

Molecular Intervention

Derazantinib is a pan-FGFR inhibitor. This means it works at the molecular level to block several types of these antennas (specifically FGFR1, FGFR2, and FGFR3).

1. Binding: Once the patient swallows the tablet, the drug travels through the bloodstream and enters the cancer cells.
2. Blocking the Energy Site: It binds to a specific pocket on the FGFR protein called the ATP-binding site. This is where the protein normally gets the energy it needs to send growth signals.
3. Cutting the Signal: By “plugging” this pocket, derazantinib prevents the protein from working. The constant growth signal is cut off.
4. Tumor Shrinkage: Without the signal to grow, the cancer cells stop dividing and may eventually die. Derazantinib also blocks other proteins like RET and DDR2, which can further help stop the cancer from building its own blood supply.

FDA-Approved Clinical Indications

As derazantinib is currently in the investigational stage, it does not have standard FDA-approved indications for the general public yet. However, it is being used in clinical settings for the following:

Oncological Uses (In Clinical Trials):

• Intrahepatic Cholangiocarcinoma (iCCA): This is a rare cancer of the bile ducts inside the liver. It is specifically used for patients whose tumors have an “FGFR2 gene fusion.”
• Urothelial Cancer: Cancers of the bladder or urinary tract that have FGFR mutations.
• Gastric (Stomach) Cancer: Used in cases where the tumor shows high levels of FGFR activity.

Non-oncological Uses:

• There are currently no non-cancer uses for derazantinib.

Dosage and Administration Protocols

Because derazantinib is a pill, it is much more convenient for patients than intravenous infusions. The dosage is carefully determined by the doctor based on the specific clinical trial protocol.

Adjustments for Insufficiency:

• Hepatic (Liver) Insufficiency: Since the drug is processed in the liver, patients with liver damage may require a lower dose to avoid toxicity.
• Renal (Kidney) Insufficiency: Current data suggest that mild kidney issues do not require major changes, but severe cases are handled on a case-by-case basis by the oncologist.

Clinical Efficacy and Research Results

Recent data (2020–2025) from trials like the FIDES-1 study have shown promising results for patients with bile duct cancer who have failed other treatments.

• Tumor Response: In studies of FGFR2-fusion positive bile duct cancer, approximately 21% to 25% of patients saw their tumors shrink significantly (Objective Response Rate).
• Disease Control: Over 70% of patients experienced “Disease Control,” meaning their cancer either shrank or stayed the same size without growing further for a period of time.
• Progression-Free Survival (PFS): In clinical trials, the median time patients lived without their disease getting worse was approximately 6 to 8 months, which is considered a positive outcome for advanced bile duct cancer.

Safety Profile and Side Effects

Derazantinib is generally better tolerated than standard chemotherapy, but because it blocks proteins that are also used by some healthy cells, side effects can occur.

Black Box Warning

• None. There is currently no FDA Black Box Warning for derazantinib.

Common Side Effects (>10%):

• Hyperphosphatemia: An increase in phosphorus levels in the blood. This happens because FGFR signals also help the kidneys manage minerals.
• Eye Changes: Dry eyes, blurred vision, or light sensitivity.
• Nail and Skin Changes: Dry skin, rashes, or nails that become brittle or lift away.
• Taste Changes: Foods may taste different or metallic.

Serious Adverse Events:

• Retinal Detachment/Eye Damage: In rare cases, the drug can cause fluid to build up under the retina in the eye.
• Liver Enzyme Elevation: Changes in blood tests that show the liver is under stress.

Management Strategies:

• For High Phosphorus: Patients are often put on a low-phosphate diet or given “phosphate binders” (medicine that stops phosphorus from being absorbed).
• For Dry Eyes: Doctors often prescribe preservative-free lubricating eye drops.

Research Areas

In the field of Immunotherapy and Combinations, derazantinib is being researched to see if it can help other drugs work better. There is current research looking at combining derazantinib with “checkpoint inhibitors” (a type of immunotherapy). Scientists believe that by blocking FGFR, derazantinib might make the environment around the tumor “friendlier” for the body’s immune cells to enter and fight the cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Genetic Testing: A biopsy or blood test (liquid biopsy) must confirm an FGFR fusion or mutation. The drug will not work if this marker is missing.
• Eye Exam: A baseline exam by an eye specialist (ophthalmologist) is required.
• Blood Panel: Tests for phosphorus levels and liver function.

Precautions During Treatment:

• Avoid certain medications: Some drugs (like strong CYP3A inhibitors) can change how derazantinib is processed. Always share your full medication list with your doctor.
• Monitor Vision: If you see “floaters,” flashes of light, or sudden blurriness, contact your medical team immediately.

“Do’s and Don’ts” List:

• DO take the pill at the same time every day to keep the drug level steady.
• DO report skin rashes or nail changes early so they can be treated with creams.
• DON’T eat large amounts of high-phosphorus foods (like processed cheeses, nuts, and dark sodas) unless instructed.
• DON’T stop taking the medication without talking to your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Derazantinib is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for standard clinical use outside of clinical trials. Always consult with a qualified healthcare professional regarding diagnosis, treatment options, and your eligibility for clinical research.